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a b s t r a c t
Central giant tumors commonly occur in long bones. In the oral and maxillofacial region, a counter-
part coined with the term Central giant cell granuloma exists. Choung and Kaban classiﬁed central giant
cell granulomas based on clinical and radiographic ﬁndings. The classiﬁcation includes aggressive and
non-aggressive variants. However, to date there has beennomolecularmethod of distinguishing the vari-
ants. Different lines of treatment had been reported. The aggressive form showed high recurrence rates
with conservative surgical treatment. Intra-lesional steroid, calcitonin, interferon, bisphosphonates and
denosumab; have been administered as a treatment lines. Several reports support the injection of intra
lesional steroids and its successful outcome. An Egyptian, nine years old female presented with a facial
swelling affecting lower left side of the mandible. Biopsy conﬁrmed it to be a CGCG. The treatment plan
was intralesional steroid injections to avoid resection of themandible. The treatment showed acceptable
progress but was associated with cushinoid appearance of patient. This forced the operating team to
halt the steroid injections and resolute to adjunctive surgical curettage yet sparing the mandible from
resection. One-year follow up showed no recurrence, however, the patient still suffers mild cushinoid
appearance.
© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Central giant cell granulomas (CGCGS) are lesions of speculative
nature. The proliferating cell is the ﬁbroblast. The histological fea-
tures include the presence of newly formed blood vessels and the
identifying feature of multinucleated giant cells. The lesion affects
the mandible more than the maxilla. The lesion commonly affects
the region anterior the ﬁrst permanent molar. Moreover, there is
a predilection toward affecting females. The lesion is common in
children and young adults. Most of these lesions appear prior to
the age of thirty [1–2].
Choung and Kaban classiﬁed CGCGS based on clinical and
radiographic ﬁndings. The classiﬁcation includes aggressive and
non-aggressive variants. However, to date, there has been no
molecular method of distinguishing the variants. A CGCG was
considered non aggressive if it displayed slow almost asymp-
tomatic growth. This growth would not be associated with cortical
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perforationsor root resorption. The lesion’s extensionwouldbe less
than ﬁve centimeter in size. This variant was associated with low
rate of recurrence. On the other hand, aggressive CGCGS displayed
all thepreviouslymentioned features.Hence, itwasassociatedwith
a higher rate of recurrence [1–2].
Surgical curettage showed high recurrence rate in case of
aggressive lesions [3], so resection with and without continuity
defects was reported to prevent recurrence.
Intra-lesional injections were considered among the possible
means of treatment which may be either intralesional steroid
[4], intralesional calcitonin [5], intralesional interferon [6], intrale-
sional bisphosphonates [7] and denosumab [8] (a monoclonal
antibody that binds RANKL and directly inhibits osteoclastoge-
nesis). The concept of using medical alternatives or adjuncts to
surgery was to evade the need for resection and reconstruction in
this young group of patients.
We present a case report in which an aggressive variant of
central giant cell granuloma was managed using a combined pro-
tocol. This protocol entailed intralesional corticosteroid injection
followed by surgical curettage to eradicate the lesion. Although,
treatment was successful, an unreported complication occurred
during the treatment phase. The patient presented with cushon-
oid facial features during the phase of intralesional corticosteroid
http://dx.doi.org/10.1016/j.ijscr.2015.02.001
2210-2612/© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Fig. 1. Preoperative OPT.
injection. In response, the surgical team shifted to completing the
treatment by surgical curettage. Details of the case and the man-
agement protocol follow.
2. Presentation of case
A nine years old female patient presented with swelling in the
left side of the mandible related to the ipsilateral lower ﬁrst molar.
The chief complaint was pain and localized swelling, the initial
diagnosismadeby thepediatric departmentwasperiapical abscess.
A pretreatment radiograph (Fig. 1) OPT was ordered by the
pediatric resident. The OPT showed well deﬁned radiolucency
related to the mandibular left ﬁrst molar measuring 3.5 cm in
antero–posterior extension and 2 cm superior inferior extension.
The case was then referred to the oral and maxillofacial depart-
ment clinic. Upon history taking, the patient reported a history
of malignancy in large intestine, which had been managed, by
chemotherapy. Dental history was insigniﬁcant.
Clinical examination revealed a mild facial swelling on the left
side. Intraorally, a swelling related to a badly broken down lower
left 1st molar which proved to have pulpal exposure was detected
(Fig. 2). Aspiration biopsy was performed under local anesthesia.
The aspiration biopsy yielded negative results.
A multi slice CT scan over the facial bones with contrast was
ordered for further assessment of the lesion’s nature. The multi
slice CT showed wide bucco-lingual extension with perforations
through both the buccal and lingual bone plates (Figs. 3, 4, 5).
The assessment of the collected data at this point led to a
differential diagnosis list. This included central giant granuloma,
ameloblastoma, aneurismal bone cyst or odontogenic myxoma.
Fig. 2. Intraoral clinical examination.
Fig. 3. Coronal CT cuts showing bucco-lingual extension and thin rim of inferior
border remaining extension).
Incisional biopsy was scheduled under local anesthesia. Histo-
logical analysis depictedmultinucleated giant cellmost probably of
ﬁbroblast origin and extravasated erythrocytes and indicated that
the lesion is giant cell lesion (Fig. 6).
Laboratory investigations were ordered, which included PTH,
blood calcium and phosphorus levels and all were within the nor-
mal levels, Furthermore, renal function tests were also normal
ruling out the possibility of primary or secondary hyperparathy-
roidism.
The lesion according to history and examination was consid-
ered aggressive. This was in accordance with criteria suggested by
Choung and Kaban.
Intra-lesional steroid injections of 5mL per injection of
(10mg/mL triamcinolone (Kenacort-A) with Lidocaine 2%) was
Fig. 4. Axial CT cuts showing extensions of lesion buccolingually and the lesion
multilocularity.
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Fig. 5. Axial CT cuts showing extensions of lesion buccolingually and perforation of
lingual plate.
Fig. 7. Progress follow up (a) OPT pretreatment in May 2013, (b) OPT showing progress at July 2013, (c) OPT showing progress at August 2013, (d) OPT showing progress at
September 2013 and (e) composite image showing pre and post treatment.
Fig. 6. H&E section of pretreatment biopsy showing giant cell.
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Fig. 8. Showing progress of cushinoid appearance through the treatment (a) May 2013, (b) October 2013, (c) November 2013.
Fig. 9. H&E section of post treatment biopsy showing newly formed woven bone.
administered with a disposable syringe for 3 months twice weekly
[9].
Follow up was made monthly by OPT. Standardization of
machine and exposure factors was undertaken. The follow up
monthly OPT starting showed gradual increase in the opacity of
the radiolucent zone denoting bone apposition (Fig. 7a–e).
During the follow up period, the patient presented with an
increase in weight. This was associated with features coincid-
ing with moon face appearance and Hirsutism associated with
Cushing’s disease (Fig. 8a–c). This alerted the surgical team to a
possibility of Cushing disease secondary to the local administration
of corticosteroids. This was not reported in the literature before.
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The local administration of the steroids was halted. Furthermore,
laboratory investigations were ordered revealing that Na/K level
was normal and that serumACTHwas normal excluding full blown
Cushing disease.
At this point, the operating team attributed the appearance to
systemic effects secondary to escape of the intralesional steroids
to the circulation. However, intra vascular injections were never
under taken throughout the treatment period.
The radioleucent lesion decreased in size gradually over the fol-
lowupperiod.At theendof followupperiod, the lesionwasdeemed
suitable for surgical curettage. Surgical curettage was performed
under general anesthesia. Accidental intraoperative bleeding took
place due to injury of lingual tissues through perforated lingual
plate and was stopped by cauterization and packing. The patient
lost about 800CC of blood and her Hb dropped from 12.1 to 9.1 and
arterial blood gas before recoverywas 7.27 leading tomild acidosis,
the anesthetic team managed the acidosis by oxygen administra-
tion postoperatively and sodium bicarbonate IV injection and ﬂuid
loss by crystalloids [10].
The post operative biopsy was histologically assessed reveal-
ing ﬁbrous tissue free from giant cell and showed with multiple
bony trabeculae specks indicating healing process and bony nature
of these specks were conﬁrmed by immunohistochemistry using
osteopontine (Fig. 9).
After one year of followup, thepatient presentedwith improved
cushonoid features. However, the patient suffered from pain and
infection related to lower left second molar attributed to loss of
vitality, the causative tooth was extracted later due to endodontic
difﬁculty.
3. Discussion
Many studies considered the aggressive form of CGCG as true
giant cell tumor of jaw based on resemblance in nature and histo-
logical featureswith giant cell tumor of long bones [11]. Findings of
another study conducted by Auclair et al. suggest that the GCT and
the CGCG represent a spectrumof a single disease processmodiﬁed
by the age of the patient and the site of occurrence [12]. However,
the term CGCG is used more in oral and maxillofacial ﬁeld than the
term giant cell tumor of bone.
Management of aggressive CGCG, as mentioned before can be
done by different protocols [2]. Resection is the recommended
treatment options in aggressive CGCG [3]. However, there are
different choices for more conservative treatment. These include
intralesional injection of steroids. Steroid injections were reported
to decrease the inﬂammatory response within the lesion (triamci-
nolone for 6 weeks) [4].
The complication that presented with this case was assessed
retrospectively. The operating team believed the cushonoid pre-
sentation could be attributed to the escape of the intralesional
steroids toward the highly vascularized lingual tissues. Hence,
although direct intravascular injection did not take place, how-
ever, the steroids found their way into the circulation through the
perforated lingual cortex.
4. Conclusion
In summary, this case report raises a warning sign when
using intralesional corticosteroids in treatment of central giant cell
granulomas. Although this treatment line has been proved effec-
tive, however, caution should be taken to evade developing the
complication for which intralesional injections were preferred to
systemic injections.
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